ArticleClinical cancer research : an official journal of the American Association for Cancer Research2019

Tissue and Plasma EGFR Mutation Analysis in the FLAURA Trial: Osimertinib versus Comparator EGFR Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer.

Jhanelle E Gray et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.